SAIPARENTSai Parenterals Limited
Convert to ideaHealthcare · Pharmaceuticals
The verdict combines business quality, price and timing. Sign in free to see it.
Sign in freeMomentum from moving averages, Supertrend and RSI.
5 forensic issues found. Sign in to see which.
Valuation Metrics
Q2 FY2027Intrinsic value, Graham number and DCF against today's price
5 found · risk elevated
Quality, growth, balance sheet and earnings quality behind the score
ⓘ Based on fundamental & forensic analysis. Always verify against official filings and consult a financial advisor.
Financial Metrics
Comparing Q2 FY2027 vs undefined undefined
| Quarter | Revenue | Net Profit | OPM | NPM | EPS | Int. Cover |
|---|---|---|---|---|---|---|
| Q2 FY2027 | ₹195 Cr | ₹11 Cr | 7.77% | 5.39% | ₹2.38 | 2.1x |
| Q1 FY2027 | ₹179 Cr | ₹8 Cr | 8.62% | 4.43% | ₹1.79 | 2.0x |
| Q4 FY2026 | ₹198 Cr | ₹13 Cr | 9.05% | 6.65% | ₹4.02 | 2.5x |
| Q3 FY2026 | ₹96 Cr | ₹-7 Cr | -9.72% | -6.93% | ₹-2.22 | -1.1x |
Momentum score, 1-year chart, moving averages, support and resistance.
Turnaround stage, and how each measure moved over 3 years against the company's own range.
Order wins, capex, pledges, rating actions and every material filing.
Management guidance, Q&A highlights and whether they delivered what they said.
The earnings call read across investor dimensions.
Promoter, FII and mutual fund holding, and what changed this quarter.
Similar-size peers in Pharmaceuticals
Compare with peers →Sai Parenteral's Limited, a pharmaceutical formulations company, engages in the branded generic formulations and contract development and manufacturing businesses in India and internationally. Its portfolio includes formulation products across various therapeutic areas, such as cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements, analgesics, and dermatology in various dosage forms, including injectables, tablets, capsules, liquid orals, and ointments. The company was founded in 1988 and is based in Hyderabad, India.
Note: This comprehensive analysis combines technical data, fundamental data, and investment thesis. Always do your own research and consider your personal risk tolerance before investing.